Advances in ovarian cancer: Using genomics and optimizing maintenance therapy

Due to its high mortality and morbidity rates, ovarian cancer remains one of the most challenging diseases to manage. However, significant progress in genomic testing has helped to identify patient-specific tumor characteristics, enabling clinicians to tailor therapies with greater precision and improve outcomes for specific patient subsets.

In the May issue of The American Journal of Managed Care’s Evidence Based Oncology, oncology pharmacist Amy VanGalder explore how advances in genomic profiling and maintenance therapies are driving more personalized, evidence-based care while minimizing adverse reactions. She also addresses the ongoing challenges that remain despite these advances.

Read article.